Академический Документы
Профессиональный Документы
Культура Документы
CHOLINERGIC PHARMACOLOGY II
Muscarinic receptors
• Location of muscarinic receptors:
• On tissues innervated by postganglionic parasympathetic nerve fibres:
• Heart
• GIT smooth muscle
• Bronchi
• Eye
• Glands
• On tissues innervated by postganglionic cholinergic sympathetic nerve fibres:
• Sweat glands on the skin
• All the effects on smooth muscle are mediated by M3 receptors which act to increase the levels of intracellular Ca
via IP3. This generally causes constriction.
• The exception is in the blood vessels. Why?
• The blood vessels are lined by a layer of endothelium, with the smooth muscle located
underneath. When an agonist binds to the M3 receptor on the endothelial cells, it stimulates the
release of NO by these cells. NO diffuses down to the smooth muscle cells where it causes
relaxation of the smooth muscle, and hence vasodilation. If the endothelium were removed,
agonists acting directly on the smooth muscle M3 receptor would cause vasoconstriction.
• Hence, the vasodilation is a result of the indirect action of an M3 agonist.
• Note that blood vessels do not receive parasympathetic innervation and so vasodilation caused
by muscarnic receptors only occurs as a result of circulating muscarinic agonists. (Not due to
Ach released from nerve terminals)
Muscarinic antagonists
• The prototype compound is atropine
• Others:
• Scopolamine
• Able to pass through BBB
• Homatropine
• Much shorter action than atropine
• It is the drug of choice when doing investigations of the eye, since it dilates the pupil for a short
time only.
• An antagonist binds to the same site as an agonist but has no effect of its own. Therefore, to see the effects of an
agonist, you need to have the effects of the agonist present first.
• e.g. The hear has resting vagal tone. This means that at rest, the vagus nerve is controlling the heart via
Ach. If, while at rest, atropine is given, it will block the M2 receptor so that Ach cannot work and so you
get a faster heart rate than it was initially. (The atropine did not cause the tachycardia directly).
• Say that the resting heart has go no nervous input. If atropine is given, it will block the M2 receptor but
we would not see any effect because three was no agonist activity to start off with.
• Analogy:
• Say you are riding a bike and you put on the brakes (antagonist). The brakes will cause the bike
to stop, so you say that the antagonist stops the bike. However, you can only see this effect if the
bike is in motion. If the bike is not moving and you put on the brakes, what will hhappen? How
do you know what effect the brakes had on the bike?
• Blood vessels have no parasympathetic innervation from the adventitia, it is only sympathetic. Hence, the resting
tone of blood vessels is not mediated by Ach. If atropine is given, it will block the M3 receptor but will not remove
endogenous tone. A side effect of atropine is that it will stimulate the release of histamine, which causes
vasodilation.
6. Parkinson's disease
• Benztropine
7. Motion sickness
• Hyoscine
8. Eye examination
• Homatropine
• Favoured because it passes through the conjunctiva easily and has a brief duration of action.
Nicotinic receptors
• Found in 2 major areas:
1. In autonomic ganglia
2. At skeletal NMJ
• Both types of receptors are clearly related, but they are different enough to be recognised by different drugs.
• The receptors are part of an ion channel.
• The ion channel is made up of α, β, γ, δ subunits, which form a pore.
• The 2 α subunits are the nicotinic receptor portion of the channel which bind Ach.
• A whole variety of α, β, γ and δ subunits have been discovered. Therefore, there may be a whole variety of N
receptors based on different combinations of these subunits.
Nicotinic agonists
• None of therapeutic use
• Nicotine
• Stimulate particularly ganglionic N receptors (also NMJ to some extent)
• Lobeline
• Similar to nicotine.
• Given to smokers in an attempt to stop smoking (by replacing nicotine addiction with lobeline addiction)
• Dimethyl phenylpipenzinium (DMPP)
• Selective for ganglionic N receptors